PLASOMA Efficacy & Technology Health (PETH) Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-01

Study Completion Date

2023-04-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to examine beneficial effects of PLASOMA treatment compared to the standard of care on chronic venous leg ulcers (VLU) that match the size of the plasma area of the pad.

The intention is that the data obtained with this study will be used to:

1. Demonstrate comparative performance of PLASOMA (for two treatment frequencies)
2. Provide evidence for health technology assessments (HTA) of PLASOMA

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PLASOMA Ultimate Safety & Efficacy Study

NCT04828304

Diabetic Foot Ulcer Venous Leg Ulcer Pressure Ulcer +4 more

COMPLETED NA

Cold atmOspheric plaSMa Therapy Versus standArd Wound Care in Diabetic Foot and Venous Leg ulcerS

NCT07251426

Diabetic Foot Ulcer Venous Leg Ulcer

NOT_YET_RECRUITING NA

PICO Venous Leg Ulcers (VLU) Reimbursement Study

NCT06510777

Venous Insufficiency Venous Leg Ulcer

TERMINATED NA

Study to Evaluate the PICO 14 Negative Pressure Wound Therapy System in the Management of Acute and Chronic Wounds

NCT05234632

Surgical Incision Ulcer Foot Ulcer Venous +3 more

TERMINATED

Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers

NCT01853384

Venous Ulcer Venous Stasis Ulcer Ulcer

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The PETH study will be an open label three-armed randomized controlled trial (RCT) on chronic VLU. The study will be performed at one study site in the Netherlands.

The three arms are:

* Control group: standard care for 12 weeks or until healing, whichever occurs first;
* Treatment group-1: standard care + PLASOMA treatment once per week for 12 weeks or until healing, whichever occurs first;
* Treatment group-2: standard care + PLASOMA treatment twice per week for 12 weeks or until healing, whichever occurs first.

After the treatment period there will be two follow up timepoints: 2 weeks after the end of the treatment period (FU1) and 12 weeks after the end of the treatment period (FU2).

Subjects will be allocated to one of the three arms according to a pre-defined randomization schedule.

Primary study parameters/outcome of the study:

Evaluate the percentage of wounds healed after 12 weeks of treatment with PLASOMA for two treatment frequencies: once per week and twice per week.

This will be done by comparing the treatment groups with the control group

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Leg Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Group Type NO_INTERVENTION

No interventions assigned to this group

1x PLASOMA

Group Type EXPERIMENTAL

PLASOMA

Intervention Type DEVICE

Treatment with cold plasma device

2x PLASOMA

Group Type EXPERIMENTAL

PLASOMA

Intervention Type DEVICE

Treatment with cold plasma device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PLASOMA

Treatment with cold plasma device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

INCL1: have a slow-healing or non-healing lower leg ulcer presumed to be caused by venous insufficiency (VLU). The wound should have insufficient healing (\<30% surface area reduction) during the last 2 weeks of standard wound care.

INCL2: have a wound with a minimum wound surface area of 0.5 cm2 and a maximum diameter of 6 cm (\~28 cm2 wound surface area for circular wounds).

INCL3: have an Ankle Brachial Pressure Index (ABPI) between 0.8 and 1.3. Note 1: subject can be included based on a VLU diagnosis from anamnesis. Make sure an ABPI measurement is performed as soon as possible to verify the diagnosis. The subject has to be excluded if the ABPI is not between 0.8 and 1.3.

Note 2: For diabetic patients an ABPI measurement is not always reliable. Therefore, diabetic patients can be included based on a VLU diagnosis from anamnesis, but no ABPI measurement needs to be performed.

INCL4: have a minimum age of 18 years old.

INCL5: For home care treatments only: there is a grounded wall socket available for connection of PLASOMA.

Exclusion Criteria

EXCL1: the subject has one or more of the following contraindications for PLASOMA:

* the wound is very exudative, i.e. wounds in which moisture is visible again within a few minutes after patting dry.
* any implanted active electronic device, such as a pacemaker, is present.
* an electronic medical device is attached to the body, including electronic life support equipment, hearing aids, glucose sensors and insulin pumps. If the sole purpose of the medical device is monitoring, the subject is not excluded, but it should be noted that use of PLASOMA together with such devices has not been tested and may lead to erroneous operation of the attached device during PLASOMA treatment.

Note: no exclusion if electronic medical device will be detached during PLASOMA treatment.

* a metal implant (including a stent) is present in the treatment area, i.e. the area between pad and electrode.
* a conductive connection from outside to inside the body at or near the heart is present, e.g. a catheter with electrolyte fluid.
* the subject has epilepsy
* the subject is pregnant

EXCL2: the subject uses systemic antibiotics.

EXCL3: the subject has any known malignant wound degeneration.

EXCL4: the subject receives treatment with immunosuppressive agents or oral corticosteroids; no exclusion if subject has received a stable dose for at least 2 months and the oral corticosteroid dose does not exceed 7.5 mg/day prednisone or equivalent.

EXCL5: the subject is receiving or likely to receive advanced wound dressings or advanced therapies- such as negative pressure therapy, hyperbaric oxygen therapy, biologicals (e.g. skin substitutes, growth factors), electrophysical therapy - for the to-be-treated wound.

EXCL6: the subject cannot (agree to) comply with the SOC.

EXCL7: the subject participates in another study which is likely to compromise the outcome of the PETH study or the feasibility of thesubject fulfilling the PETH study.

EXCL8: the subject is unable to provide consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No